Coronaviruses are the causative agents of several recent outbreaks, including the COVID-
19 pandemic. One therapeutic approach is blocking viral binding to the host receptor. As …

Background: Tumor treating fields (TTF) was first approved for treatment of glioblastoma.
Recently, the LUNAR study demonstrated that TTF+ standard therapy (ST) extended survival …

Tumor treating fields (TTFields) are among clinically active anticancer modalities that utilize
low‐intensity, intermediate frequency (IF), and alternating electric fields (AEFs) to selectively …

Tumor treating fields (TTFields)-an intermediate-frequency, electric field therapy-has
emerged as a promising alternative therapy for the treatment of solid cancers. Since the first …

Abstract Purpose Mesenchymal stromal cells (MSCs) within the glioblastoma
microenvironment have been shown to promote tumor progression. Tumor Treating Fields …

Simple Summary Glioblastoma is one of the worst cancer types and the most common
cancer originating within the brain. Patients afflicted by glioblastoma suffer from poor …

Tumor Treating Fields (TTFields) in combination with chemotherapy and/or radiotherapy
have been clinically reported to provide prolonged overall survival in glioblastoma patients …

Tumor Treating Fields (TTFields), low-intensity electric fields in the frequency range of 100-
500 kHz, exhibit antimitotic activity in cancer cells. TTFields were approved by the US Food …

Tumor-treating fields (TTFields) are alternating electrical fields of intermediate frequency
and low intensity that can slow or inhibit tumor growth by disrupting mitosis division of …

Glioblastoma is the most common and lethal form of brain cancer, with a median survival of
15 months after diagnosis and a 5 year survival rate of only 5% with current standard of care …